Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| AppLovin | Palo Alto Networks | Pfizer | |
|---|---|---|---|
| Moat rating | narrow The filing's own words support a narrow moat. Auctions run 'at vast scale and at microsecond-level speeds,' revenue is earned only 'when our advertisers achieve their return on advertising spend targets,' and FY2025 adjusted EBITDA margin was 82.3%. What limits the width: clients 'are not required to enter into long-term agreements' and 'Substantially all of the Company's contracts with customers are cancelable at any time'; the solutions 'primarily operate in the mobile app ecosystem and specifically mobile gaming'; and distribution runs through 'the Apple App Store, the Google Play Store, and Meta' while AppLovin relies 'in part on IDFA.' | narrow Real but bounded. The FY2025 10-K's own Competition section calls the enterprise security industry "intensely competitive" and names four categories of rival — platform incumbents (Cisco, Microsoft, Alphabet), independent security vendors (Check Point, Fortinet, CrowdStrike, Zscaler, Wiz), point-product startups, and the public cloud vendors — while conceding that "some of our competitors may have substantially greater financial, technical, and other resources, greater name recognition, larger sales and marketing budgets, broader distribution, more diversified product lines, and larger and more mature intellectual property portfolios." That record supports a defensible position, not an unassailable one: narrow, not wide. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | network effects Network effects, with a caveat. The 10-K states the loop: as more advertisers use the solutions 'we gain access to more data regarding users and user engagement,' 'further strengthening our scaled distribution,' and 'As our distribution grows, we gain better insights for Axon AI.' The mechanism is two-sided matching of advertiser demand to publisher supply, though much of the force comes from data-and-learning scale. It is not switching costs, since contracts are 'cancelable at any time,' nor intangibles or IP, since 'there can be no assurance that we will adequately protect our intellectual property or that it will provide any competitive advantage.' | switching costs The 10-K describes an installed estate standardised on one operating system — "All of our hardware and software firewalls incorporate the PAN-OS operating system and include the same rich set of features, ensuring consistent operation across our entire product line" — across hardware, containerised CN-Series and virtual VM-Series form factors, centrally administered through Panorama and Strata Cloud Manager. That estate is monetised as recurring contract: subscription and support was 80.5% of total revenue in fiscal 2025 (80.0% in fiscal 2024, 77.1% in fiscal 2023), on terms "typically one to five years." The company's own risk factors describe the friction from the other side — customers "may face real or perceived switching costs when switching to our solutions from legacy security vendors" and "have often invested substantial personnel and financial resources to design and operate their networks... [and] may prefer to purchase from their existing suppliers rather than add or switch to a new supplier." As the incumbent in most of those estates, that friction now runs in Palo Alto's favour. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | at parity The filing discloses no share of any market, names 'Meta, Google, Amazon, and Unity Software' as competitors, and concedes rivals 'may have greater resources' and 'better technological or data analytics capabilities, or stronger brands or competitive positions in certain product segments.' Its one positional statement is parity language: 'We believe we compete favorably with respect to these factors.' Two unquantified points cut upward: Meta and Google are also clients, and MAX is called 'the preferred in-app bidding solution for many publishers worldwide.' | co leader The 10-K claims parity-plus, not primacy: "We believe we generally compete favorably with our competitors on the basis of these factors as a result of the features and performance of our portfolio, the ease of integration of our security solutions with technological infrastructures, and the relatively low total cost of ownership of our products," and reports that its "products and services have been recognized as leading in 25 categories by third-party industry analysts firms." It qualifies that immediately by conceding that some competitors carry greater resources, name recognition and distribution. Independent analyst placements match a co-leader read rather than a sole-leader one — a Leader in the inaugural 2025 Gartner Magic Quadrant for Hybrid Mesh Firewalls, a Leader for the third consecutive time in the 2025 Magic Quadrant for SASE Platforms, and a Leader in the 2026 Magic Quadrant for Endpoint Protection Platforms for the fourth consecutive year — in categories that name other Leaders too. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | strong Strong, with the mechanism shown. The 10-K states that 'Advertisers are charged dynamically based on their campaign goals , rather than a simple fixed price per impression or per action.' Growth composition is the evidence: FY2025 revenue +70% with 'the volume of installations increased 3% and net revenue per installation increased 72%'; H1 2026 +56% with per-installation revenue +75% against 'a decrease in the volume of installations of 10%.' Adjusted EBITDA margin was 82.3% in FY2025 and 84.2% in H1 2026, though payment is performance-contingent and contracts cancel at will. | moderate Moderate, with the evidence pointing both ways in the same filing. Gross margin computed from the three years of income statements inside this FY2025 10-K runs 72.3% (fiscal 2023), 74.3% (fiscal 2024) and 73.4% in fiscal 2025 on revenue of $9.22 billion — against 68.8% in fiscal 2022 as reported in the prior-year 10-K (accession 0001327567-24-000029, filed September 6, 2024). Over the same span subscription and support rose from 77.1% to 80.5% of revenue: a mix shift toward software that has been margin-accretive, not margin-destructive, which is the direct answer to whether platformisation is simply discounting. Against that, the 10-K's risk factors state plainly that sales prices "may decline for a variety of reasons, including competitive pricing pressures, discounts, a change in our mix... or promotional programs," that the company "anticipate[s] that the sales prices and gross profits for our products could decrease over product life cycles," and that it "has also experienced demands for customer financing and deferred payments." Pricing is defended by bundle economics rather than commanded outright. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | One reportable segment: an AI-priced auction matching advertiser demand to publisher supply, where 'Revenue from Axon Ads Manager comprises substantially all of our revenue.' The filed flywheel is real - more advertiser spend yields more user-engagement data, 'further strengthening our scaled distribution,' which feeds Axon AI - and it converts: FY2025 revenue $5.48B, up 70%, at an 82.3% adjusted EBITDA margin, carried by price (net revenue per installation +72%) not volume (installations +3%). What the filing does not evidence is a lock. Contracts are cancelable at any time, revenue concentrates in mobile gaming, and the distribution and identifier layers belong to Apple, Google and Meta - two of whom are simultaneously named competitors and disclosed clients. Wide margins with no disclosed structural lock is narrow. | A deployed firewall estate is the anchor. Every Palo Alto firewall — appliance, VM-Series, CN-Series, Cloud NGFW — runs the same PAN-OS with the same feature set and is managed from one console, so the security policy, the operator skills and the integration work are all specific to the vendor, and 80.5% of fiscal 2025 revenue is the recurring subscription and support contract sitting on top of it (10-K, Business and Risk Factors). Platformisation is the attempt to convert that anchor into wallet share: the 10-K states the strategy as helping customers "simplify their security architectures through consolidating disparate point products" by packaging offerings "into a tightly integrated architecture," and the acquisitions are consistent with it — IBM's QRadar assets in August 2024 "to help accelerate the growth of our Cortex business," Protect AI in July 2025, and the CyberArk agreement signed in July 2025. The evidence that consolidation is real rather than a discount: remaining performance obligation grew 36% year over year to $18.4 billion against 31% revenue growth in the quarter ended April 30, 2026 (Palo Alto Networks FQ3 2026 results release, June 2, 2026) — contracted future obligation compounding faster than recognised revenue, which is the opposite of what buying revenue with price would produce. The counterweight is disclosed in the same filings: the 10-K warns sales prices "may decline for a variety of reasons, including competitive pricing pressures, discounts," anticipates that "sales prices and gross profits for our products could decrease over product life cycles," and reports "demands for customer financing and deferred payments." Against CrowdStrike in security operations and Zscaler in SASE, Palo Alto is competing across the whole surface rather than defending a monopoly on any one of them — hence a narrow moat, not a wide one. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Demand-side AI ad platform: it monetizes third-party mobile-game publishers' inventory and sells outcomes to advertisers, so it sits downstream of Apple/Google app distribution and Apple's IDFA identifier layer and upstream of publisher monetization. Meta and Google are simultaneously named competitors and disclosed clients. Single reportable segment after the June 2025 Apps divestiture. | A security-software consumer of the AI stack rather than a supplier to it — it buys compute to run Precision AI and now sells protection for the stack itself through Prisma AIRS (AI model scanning, posture management, red teaming, runtime and AI-agent security). Distribution is two-tier and concentrated: 44.2% of fiscal 2025 revenue came through three distributors and more than 8,500 channel partners, while no single end-customer exceeded 10% of revenue in fiscal 2025, 2024 or 2023. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.11 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |